Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus

Jianxun Wang, Masayuki Mizui, Li Fan Zeng, Roderick Bronson, Michele Finnell, Cox Terhorst, Vasileios C. Kyttaris, George C. Tsokos, Zhong-Yin Zhang, Maria I. Kontaridis

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is a devastating multisystemic autoimmune disorder. However, the molecular mechanisms underlying its pathogenesis remain elusive. Some patients with Noonan syndrome, a congenital disorder predominantly caused by gain-of-function mutations in the protein tyrosine phosphatase SH2 domain-containing PTP (SHP2), have been shown to develop SLE, suggesting a functional correlation between phosphatase activity and systemic autoimmunity. To test this directly, we measured SHP2 activity in spleen lysates isolated from lupus-prone MRL/lpr mice and found it was markedly increased compared with that in control mice. Similar increases in SHP2 activity were seen in peripheral blood mononuclear cells isolated from lupus patients relative to healthy patients. To determine whether SHP2 alters autoimmunity and related immunopathology, we treated MRL/lpr mice with an SHP2 inhibitor and found increased life span, suppressed crescentic glomerulonephritis, reduced spleen size, and diminished skin lesions. SHP2 inhibition also reduced numbers of double-negative T cells, normalized ERK/MAPK signaling, and decreased production of IFN-γ and IL-17A/F, 2 cytokines involved in SLE-associated organ damage. Moreover, in cultured human lupus T cells, SHP2 inhibition reduced proliferation and decreased production of IFN-γ and IL-17A/F, further implicating SHP2 in lupus-associated immunopathology. Taken together, these data identify SHP2 as a critical regulator of SLE pathogenesis and suggest targeting of its activity as a potent treatment for lupus patients.

Original languageEnglish (US)
Pages (from-to)2077-2092
Number of pages16
JournalJournal of Clinical Investigation
Volume126
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Systemic Lupus Erythematosus
Inbred MRL lpr Mouse
Interleukin-17
Autoimmunity
SH2 Domain-Containing Protein Tyrosine Phosphatases
Spleen
Noonan Syndrome
T-Lymphocytes
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Glomerulonephritis
Phosphoric Monoester Hydrolases
Blood Cells
Cytokines
Skin
Mutation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wang, J., Mizui, M., Zeng, L. F., Bronson, R., Finnell, M., Terhorst, C., ... Kontaridis, M. I. (2016). Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. Journal of Clinical Investigation, 126(6), 2077-2092. https://doi.org/10.1172/JCI87037

Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. / Wang, Jianxun; Mizui, Masayuki; Zeng, Li Fan; Bronson, Roderick; Finnell, Michele; Terhorst, Cox; Kyttaris, Vasileios C.; Tsokos, George C.; Zhang, Zhong-Yin; Kontaridis, Maria I.

In: Journal of Clinical Investigation, Vol. 126, No. 6, 01.06.2016, p. 2077-2092.

Research output: Contribution to journalArticle

Wang, J, Mizui, M, Zeng, LF, Bronson, R, Finnell, M, Terhorst, C, Kyttaris, VC, Tsokos, GC, Zhang, Z-Y & Kontaridis, MI 2016, 'Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus', Journal of Clinical Investigation, vol. 126, no. 6, pp. 2077-2092. https://doi.org/10.1172/JCI87037
Wang J, Mizui M, Zeng LF, Bronson R, Finnell M, Terhorst C et al. Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. Journal of Clinical Investigation. 2016 Jun 1;126(6):2077-2092. https://doi.org/10.1172/JCI87037
Wang, Jianxun ; Mizui, Masayuki ; Zeng, Li Fan ; Bronson, Roderick ; Finnell, Michele ; Terhorst, Cox ; Kyttaris, Vasileios C. ; Tsokos, George C. ; Zhang, Zhong-Yin ; Kontaridis, Maria I. / Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. In: Journal of Clinical Investigation. 2016 ; Vol. 126, No. 6. pp. 2077-2092.
@article{ba0a53f1c38f426c8c976a87e7716bad,
title = "Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus",
abstract = "Systemic lupus erythematosus (SLE) is a devastating multisystemic autoimmune disorder. However, the molecular mechanisms underlying its pathogenesis remain elusive. Some patients with Noonan syndrome, a congenital disorder predominantly caused by gain-of-function mutations in the protein tyrosine phosphatase SH2 domain-containing PTP (SHP2), have been shown to develop SLE, suggesting a functional correlation between phosphatase activity and systemic autoimmunity. To test this directly, we measured SHP2 activity in spleen lysates isolated from lupus-prone MRL/lpr mice and found it was markedly increased compared with that in control mice. Similar increases in SHP2 activity were seen in peripheral blood mononuclear cells isolated from lupus patients relative to healthy patients. To determine whether SHP2 alters autoimmunity and related immunopathology, we treated MRL/lpr mice with an SHP2 inhibitor and found increased life span, suppressed crescentic glomerulonephritis, reduced spleen size, and diminished skin lesions. SHP2 inhibition also reduced numbers of double-negative T cells, normalized ERK/MAPK signaling, and decreased production of IFN-γ and IL-17A/F, 2 cytokines involved in SLE-associated organ damage. Moreover, in cultured human lupus T cells, SHP2 inhibition reduced proliferation and decreased production of IFN-γ and IL-17A/F, further implicating SHP2 in lupus-associated immunopathology. Taken together, these data identify SHP2 as a critical regulator of SLE pathogenesis and suggest targeting of its activity as a potent treatment for lupus patients.",
author = "Jianxun Wang and Masayuki Mizui and Zeng, {Li Fan} and Roderick Bronson and Michele Finnell and Cox Terhorst and Kyttaris, {Vasileios C.} and Tsokos, {George C.} and Zhong-Yin Zhang and Kontaridis, {Maria I.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1172/JCI87037",
language = "English (US)",
volume = "126",
pages = "2077--2092",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "6",

}

TY - JOUR

T1 - Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus

AU - Wang, Jianxun

AU - Mizui, Masayuki

AU - Zeng, Li Fan

AU - Bronson, Roderick

AU - Finnell, Michele

AU - Terhorst, Cox

AU - Kyttaris, Vasileios C.

AU - Tsokos, George C.

AU - Zhang, Zhong-Yin

AU - Kontaridis, Maria I.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Systemic lupus erythematosus (SLE) is a devastating multisystemic autoimmune disorder. However, the molecular mechanisms underlying its pathogenesis remain elusive. Some patients with Noonan syndrome, a congenital disorder predominantly caused by gain-of-function mutations in the protein tyrosine phosphatase SH2 domain-containing PTP (SHP2), have been shown to develop SLE, suggesting a functional correlation between phosphatase activity and systemic autoimmunity. To test this directly, we measured SHP2 activity in spleen lysates isolated from lupus-prone MRL/lpr mice and found it was markedly increased compared with that in control mice. Similar increases in SHP2 activity were seen in peripheral blood mononuclear cells isolated from lupus patients relative to healthy patients. To determine whether SHP2 alters autoimmunity and related immunopathology, we treated MRL/lpr mice with an SHP2 inhibitor and found increased life span, suppressed crescentic glomerulonephritis, reduced spleen size, and diminished skin lesions. SHP2 inhibition also reduced numbers of double-negative T cells, normalized ERK/MAPK signaling, and decreased production of IFN-γ and IL-17A/F, 2 cytokines involved in SLE-associated organ damage. Moreover, in cultured human lupus T cells, SHP2 inhibition reduced proliferation and decreased production of IFN-γ and IL-17A/F, further implicating SHP2 in lupus-associated immunopathology. Taken together, these data identify SHP2 as a critical regulator of SLE pathogenesis and suggest targeting of its activity as a potent treatment for lupus patients.

AB - Systemic lupus erythematosus (SLE) is a devastating multisystemic autoimmune disorder. However, the molecular mechanisms underlying its pathogenesis remain elusive. Some patients with Noonan syndrome, a congenital disorder predominantly caused by gain-of-function mutations in the protein tyrosine phosphatase SH2 domain-containing PTP (SHP2), have been shown to develop SLE, suggesting a functional correlation between phosphatase activity and systemic autoimmunity. To test this directly, we measured SHP2 activity in spleen lysates isolated from lupus-prone MRL/lpr mice and found it was markedly increased compared with that in control mice. Similar increases in SHP2 activity were seen in peripheral blood mononuclear cells isolated from lupus patients relative to healthy patients. To determine whether SHP2 alters autoimmunity and related immunopathology, we treated MRL/lpr mice with an SHP2 inhibitor and found increased life span, suppressed crescentic glomerulonephritis, reduced spleen size, and diminished skin lesions. SHP2 inhibition also reduced numbers of double-negative T cells, normalized ERK/MAPK signaling, and decreased production of IFN-γ and IL-17A/F, 2 cytokines involved in SLE-associated organ damage. Moreover, in cultured human lupus T cells, SHP2 inhibition reduced proliferation and decreased production of IFN-γ and IL-17A/F, further implicating SHP2 in lupus-associated immunopathology. Taken together, these data identify SHP2 as a critical regulator of SLE pathogenesis and suggest targeting of its activity as a potent treatment for lupus patients.

UR - http://www.scopus.com/inward/record.url?scp=84974623037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84974623037&partnerID=8YFLogxK

U2 - 10.1172/JCI87037

DO - 10.1172/JCI87037

M3 - Article

VL - 126

SP - 2077

EP - 2092

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 6

ER -